Omalizumab biosimilar - Harvest Moon Pharmaceuticals

Drug Profile

Omalizumab biosimilar - Harvest Moon Pharmaceuticals

Latest Information Update: 03 Jul 2015

Price : $50

At a glance

  • Originator Harvest Moon Pharmaceuticals
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Allergic asthma

Most Recent Events

  • 03 Jul 2015 Research is ongoing in USA
  • 18 Jun 2015 Omalizumab biosimilar - Harvest Moon Pharmaceuticals is available for licensing as of 18 Jun 2015.
  • 10 Jun 2015 Biosimilars no longer licensed to PanPharmaceuticals USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top